Solid Biosciences Inc. financial data

Symbol
SLDB on Nasdaq
Location
500 Rutherford Avenue, 3 Rd Floor, Charlestown, MA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 3, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 794 % -26.9%
Debt-to-equity 22.8 % -0.04%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 77.9M shares +95%
Common Stock, Shares, Outstanding 77.9M shares +100%
Entity Public Float 130M USD +153%
Common Stock, Value, Issued 78K USD +100%
Weighted Average Number of Shares Outstanding, Basic 94.4M shares +128%
Weighted Average Number of Shares Outstanding, Diluted 94.4M shares +128%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 133M USD +63.9%
General and Administrative Expense 36.7M USD +18.6%
Operating Income (Loss) -170M USD -51.4%
Nonoperating Income (Expense) 2.56M USD -73.5%
Income Tax Expense (Benefit) 0 USD
Earnings Per Share, Basic -2 USD/shares +17.2%
Earnings Per Share, Diluted -2 USD/shares +22.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 61.4M USD -4.71%
Cash, Cash Equivalents, and Short-term Investments 236M USD +38%
Assets, Current 245M USD +36.4%
Property, Plant and Equipment, Net 4.36M USD -14%
Operating Lease, Right-of-Use Asset 22.5M USD -9.35%
Other Assets, Noncurrent 247K USD -48%
Assets 274M USD +29.3%
Accounts Payable, Current 8.43M USD +144%
Accrued Liabilities, Current 19.1M USD +44%
Liabilities, Current 36.3M USD +59%
Operating Lease, Liability, Noncurrent 19.6M USD -9.33%
Liabilities 56M USD +24.9%
Accumulated Other Comprehensive Income (Loss), Net of Tax 48K USD -58.6%
Retained Earnings (Accumulated Deficit) -908M USD -22.6%
Stockholders' Equity Attributable to Parent 218M USD +30.5%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 126M USD -40.2%
Liabilities and Equity 274M USD +29.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -31.9M USD -26.4%
Net Cash Provided by (Used in) Financing Activities 190M USD +76.9%
Net Cash Provided by (Used in) Investing Activities -27.5M USD +28.6%
Common Stock, Shares Authorized 240M shares +100%
Common Stock, Shares, Issued 77.9M shares +100%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 130M USD +199%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 63.3M USD -4.58%
Interest Paid, Excluding Capitalized Interest, Operating Activities 68K USD
Deferred Tax Assets, Valuation Allowance 131M USD +42.5%
Deferred Tax Assets, Gross 137M USD +38%
Operating Lease, Liability 22.9M USD -6.58%
Depreciation 2.58M USD +7.18%
Payments to Acquire Property, Plant, and Equipment 126K USD -15.4%
Lessee, Operating Lease, Liability, to be Paid 34.2M USD -10.8%
Property, Plant and Equipment, Gross 17.8M USD -8.19%
Operating Lease, Liability, Current 2.03M USD +18.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 4.28M USD +4.23%
Lessee, Operating Lease, Liability, to be Paid, Year One 4.18M USD -5.01%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 11.3M USD -18.2%
Lessee, Operating Lease, Liability, to be Paid, Year Three 4.28M USD +3.81%
Deferred Tax Assets, Operating Loss Carryforwards 37.2M USD +124%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 4.36M USD +2.95%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 14.2M USD +64.8%
Interest Expense 88K USD -20.7%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%